Loading...
Loading...
Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec
BIIB for the study of the immune repertoire and the search for immunological biomarkers in difficult to
treat autoimmune diseases.
Under the collaboration, Adaptive's proprietary immune profiling assay,
immunoSEQ, will be used to characterize the immune repertoire of patient
samples with autoimmune disorders with high unmet medical needs. The
immunoSEQ assay uses high throughput next-generation sequencing to
characterize the repertoire of T and B cell receptors, which can be very
useful to monitor the immune status of patients with autoimmune diseases and
to assess the impact of treatments that impact or alter the immune system.
"We are delighted to collaborate with Biogen Idec to help further characterize
the immune status of patients with autoimmune diseases who are often quite
heterogeneous and therefore, difficult to treat without a more personalized
approach," said Chad Robins, CEO and Founder of Adaptive Biotechnologies.
"Partnering with Biogen Idec fits squarely with Adaptive's dual commitment to
a deeper understanding of complex diseases as well as to finding better means
to treat them."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in